Supplementary Figure 2 from A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure 2: LNCAP and DU-145 prostate cancer cells were treated with 1 or 10 μM GSK2636771 for up to 48 hours and probed with the indicated antibodies
Authors: Joaquin Mateo, Gopinath Ganji, Charlotte Lemech, Howard A. Burris, Sae-Won Han, Karen Swales, Shaun Decordova, M. Phillip DeYoung, Deborah A. Smith, Shanker Kalyana-Sundaram, Jiuhua Wu, Monica Motwani, Rakesh Kumar, Jerry M. Tolson, Sun Young Rha, Hyun Cheol Chung, Joseph P. Eder, Sunil Sharma, Yung-Jue Bang, Jeffrey R. Infante, Li Yan, Johann S. de Bono, Hendrik-Tobias Arkenau
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362405016